Stockreport

UPDATE – Ikena Oncology Announces Strategic Update

Ikena Oncology, Inc.  (IKNA) 
PDF Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first [Read more]